Upadacitinib (Rinvoq) is now indicated for patients aged 2 years or older with active polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA) who cannot tolerate […]

The US Food and Drug Administration (FDA) approved mRESVIA (mRNA-1345, Moderna), a vaccine for respiratory syncytial virus (RSV). The mRNA vaccine is approved for adults aged […]

A marketing authorization for Zegalogue (dasiglucagon, Zealand Pharma) for the treatment of severe hypoglycemia in patients aged 6 years and older with diabetes has been recommended by […]

At its May 30 meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) endorsed the approval of several cancer […]

The Committee for Medicinal Products for Human Use (CHMP) has recommended dropping a previous ban on donations of blood or plasma for fractionation from individuals who […]

In its May 2024 meeting, the European Medicines Agency (EMA) gave the go-ahead for Durveqtix to treat severe and moderately severe hemophilia B in adults who […]

The European Medicines Agency (EMA) has recommended granting a marketing authorization in the European Union for Ixchiq (Valneva Austria), the first vaccine for EU countries intended […]

The US Food and Drug Administration (FDA) has approved Onyda XR (clonidine hydrochloride) for the treatment of attention-deficit/hyperactivity disorder (ADHD), drug manufacturer Tris Pharma announced in […]